The evolving landscape of NGS in clinical oncology reveals intriguing trends, especially for solid tumor panels. Our analysis highlights the following 3 insights:
1. Dominance of Pan-Cancer Solid Tumor Panels: These panels are not just prevalent; they're integral, representing a significant 60% of testing volumes. While smaller panels are popular due to their accessibility, it's the larger panels that are leading in volumes in high-throughput labs. Interestingly, nearly all labs involved with pan-cancer panels (~90%) also diversify their testing with other NGS panel types
2. Solid Tumor Panel Growth Dynamics: The growth story here is multi-layered. In labs with a singular focus on solid tumor panels, smaller ones are poised for rapid growth, especially ex-U.S.. Yet, the larger panels, despite a slightly slower growth projection, boast higher average volumes. This dynamic shifts in multi-panel labs, where large panels are anticipated to outpace small ones in growth.
3. Underestimation of Larger Panel Adoption: Our survey suggests a potential underestimation by respondents in the speed of transitioning to larger panels. This shift could be swifter than anticipated, driven by the continued adoption of new, valuable biomarkers.
The shift towards larger panels in NGS labs might occur faster than many experts predict. The diversity in panel size preference and the rapid pace of this shift affirms that the NGS field is not just growing – it's dynamically evolving.
#NGSisUnstoppable
.png)
.png)
